Patents by Inventor Harry Brielmann
Harry Brielmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8334382Abstract: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: February 15, 2010Date of Patent: December 18, 2012Assignee: Neurogen CorporationInventors: Charles A. Blum, Harry Brielmann, Bertrand L. Chenard, Xiaozhang Zheng
-
Publication number: 20110003813Abstract: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: February 15, 2010Publication date: January 6, 2011Inventors: Charles A. Blum, Harry Brielmann, Bertrand L. Chenard, Xiaozhang Zheng
-
Patent number: 7662830Abstract: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptors activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: August 13, 2005Date of Patent: February 16, 2010Assignee: Neurogen CorporationInventors: Charles A. Blum, Harry Brielmann, Bertrand L. Chenard, Xiaozhang Zheng
-
Patent number: 7432275Abstract: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: December 12, 2003Date of Patent: October 7, 2008Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Timothy M. Caldwell, Stéphane DeLombaert, Kevin J. Hodgetts, Xiaozhang Zheng
-
Publication number: 20080153857Abstract: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: December 10, 2007Publication date: June 26, 2008Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Stephane De Lombaert, Xiaozhang Zheng
-
Patent number: 7329664Abstract: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals.Type: GrantFiled: July 16, 2004Date of Patent: February 12, 2008Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Stéphane De Lombaert, Xiaozhang Zheng
-
Publication number: 20080015183Abstract: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: September 29, 2007Publication date: January 17, 2008Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Timothy Caldwell, Stephane De Lombaert, Kevin Hodgetts, Xiaozhang Zheng, James Krause, Uri Herzberg, Taeyoung Yoon
-
Patent number: 7304059Abstract: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: February 1, 2006Date of Patent: December 4, 2007Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Timothy M. Caldwell, Stéphane De Lombaert, Kevin J. Hodgetts, Xiaozhang Zheng, Taeyoung Yoon
-
Publication number: 20070027155Abstract: Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: July 16, 2004Publication date: February 1, 2007Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Bertrand Chenard, Stephane De Lombaert, Kevin Hodgetts, Alan Hutchison, Taeyoung Yoon, Xiaozhang Zheng
-
Publication number: 20060229308Abstract: Substituted pyrimidyl-4-ylamine analogues are provided, of the Formula: (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate Vanilloid receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: July 15, 2004Publication date: October 12, 2006Applicant: Neurogen CorporationInventors: Charles Blum, Harry Brielmann, Kevin Hodgetts
-
Publication number: 20060194805Abstract: Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VR1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: April 26, 2006Publication date: August 31, 2006Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Timothy Caldwell, Daniel Cortright, Kevin Hodgetts, John Peterson, Xiaozhang Zheng
-
Publication number: 20060173003Abstract: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: February 1, 2006Publication date: August 3, 2006Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Timothy Caldwell, Stephane De Lombaert, Kevin Hodgetts, Xiaozhang Zheng, James Krause, Uri Herzberg
-
Patent number: 7074799Abstract: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: January 17, 2003Date of Patent: July 11, 2006Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Timothy M. Caldwell, Stephane De Lombaert, Kevin J. Hodgetts, Xiaozhang Zheng
-
Publication number: 20060122394Abstract: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptors activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: August 13, 2005Publication date: June 8, 2006Inventors: Charles Blum, Harry Brielmann, Bertrand Chenard, Xiaozhang Zheng
-
Publication number: 20060100245Abstract: Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: December 19, 2003Publication date: May 11, 2006Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane DeLombaert, Taeyoung Yoon, Xiaozhang Zheng
-
Publication number: 20060089354Abstract: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: December 12, 2003Publication date: April 27, 2006Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Timothy Caldwell, Stephane DeLombaert, Kevin Hodgetts, Xiaozhang Zheng
-
Publication number: 20060040964Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.Type: ApplicationFiled: July 18, 2005Publication date: February 23, 2006Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Elliott, Marlys Hammond
-
Publication number: 20050215575Abstract: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: July 16, 2004Publication date: September 29, 2005Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Stephane De Lombaert, Xiaozhang Zheng
-
Publication number: 20050033048Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.Type: ApplicationFiled: December 11, 2001Publication date: February 10, 2005Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Elliott, Marlys Hammond
-
Publication number: 20040156869Abstract: 1 Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: December 12, 2003Publication date: August 12, 2004Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Timothy M. Caldwell, Stephane De Lombaert, Kevin J. Hodgetts, Xiaozhang Zheng